API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
DWRX2008 is an innovative nanoparticle eyedrop adaptation of Envlo®(enavogliflozin), which tackles the challenge of poor retinal drug absorption from oral use, which is investigated for Diabetic Retinopathy and Macular Edema.
Lead Product(s): Enavogliflozin
Therapeutic Area: Ophthalmology Product Name: DWRX2008
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 25, 2023
Details:
Under the agreement, M8 will have the rights to register and commercialize Envlo™ (enavogliflozin) for Brazil and Mexico. Envlo™ is a SGLT2 (sodium glucose cotransporter 2) inhibitor type diabetes treatment.
Lead Product(s): Enavogliflozin
Therapeutic Area: Endocrinology Product Name: Envlo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Moksha8 Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement February 28, 2023
Details:
Envlo (enavogliflozin), an antidiabetic agent, is an orally active, best-in-class and selective sodium-glucose cotransporter-2 (SGLT-2) inhibitor. It is being developed for type-2-diabetes.
Lead Product(s): Enavogliflozin
Therapeutic Area: Endocrinology Product Name: Envlo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 27, 2023
Details:
DWP16001 (enavogliflozin) is a new diabetes drug in the SGLT-2 inhibitor class. The two combination trials, Enavogliflozin-Metformin and Enavogliflozin-Metformin-Gemigliptin combination, demonstrated non-inferiority in HbAc1 change compared to dapagliflozin 10 mg.
Lead Product(s): Enavogliflozin,Metformin,Gemigliptin
Therapeutic Area: Endocrinology Product Name: DWP16001
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2022
Details:
Enavogliflozin is an SGLT-2 inhibitor for diabetes in development by Daewoong for the first time in South Korea. The safety of Enavogliflozin has been proven through three sequential clinical trials of monotherapy, metformin combination, and Metformin-Gemigliptin combination.
Lead Product(s): Enavogliflozin,Metformin,Gemigliptin
Therapeutic Area: Endocrinology Product Name: DWP16001
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 25, 2022
Details:
In the study, researchers compared fructosamine, fasting glucose, and insulin dose changes in a group treated with insulin and Enavogliflozin once daily for eight weeks and the other group once every three days to evaluate its weight and blood pressure.
Lead Product(s): Enavogliflozin
Therapeutic Area: Endocrinology Product Name: DWP16001
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2021
Details:
Enavogliflozin administered in conjunction with diet and exercise showed statistically significant decrease in glycated hemoglobin (HbA1c) levels in comparison to the placebo starting from week 4, in type 2 diabetes patients with uncontrolled blood sugar level.
Lead Product(s): Enavogliflozin
Therapeutic Area: Endocrinology Product Name: DWP16001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2020